ArticleScientific reports2020

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.

Hera Saqub et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.